Skip to content
glp1.howSign in

Hair loss on a GLP-1: what the evidence actually shows

Hair loss is listed as an adverse reaction on the Zepbound label, and recent research shows it's a real, well-documented effect. It is most plausibly tied to rapid weight loss, and the most common type is temporary. What the evidence shows and what can help.

Updated Sep 26, 2026Evidence-backed

Hair loss on a GLP-1 is real and well documented. It most likely comes from the body's response to rapid weight loss, and there's no clear evidence yet that the drug acts on hair follicles directly. The most common type is temporary.

Is hair loss actually a GLP-1 side effect?

Yes, in the sense that it shows up more on the drug than on placebo. In the Zepbound (tirzepatide) weight-management trials, hair loss was reported by 4–5% of people on the drug and 1% on placebo, and it was more common in women (7.1%) than men (0.5%) (DailyMed, Zepbound label, revised 8/2026 (external link)). What isn't established is why: whether the drug does something to follicles or whether the shedding is simply what rapid weight loss does.

A 2026 systematic review of 24 studies found semaglutide and tirzepatide had the highest reported incidence and the most frequent signal detection in pharmacovigilance databases (Gupta et al., Science Progress, 2026, DOI (external link)). The two types reported most were telogen effluvium, a temporary, diffuse shedding triggered by physiological stress, and androgenetic alopecia. Tirzepatide was most often linked to telogen effluvium.

What adverse-event reports can and can't tell you

Reports of a symptom aren't proof the drug caused it. A pharmacovigilance study that searched four databases (the FDA's FAERS, Australia's DAEN, the EMA's EudraVigilance, and the WHO's VigiBase) found GLP-1 medications were the most-reported drug class for hair loss, led by semaglutide, liraglutide, and dulaglutide. Even so, the reports did not meet the statistical criteria for a positive safety signal (Nakhla et al., Cardiovascular Drugs and Therapy, 2024, DOI (external link)). The authors called for intensive monitoring instead of treating the link as established.

These databases collect reports, and public attention to a side effect tends to increase how often people report it, which matters for a drug class this widely discussed. A 2026 EudraVigilance analysis also found alopecia in 0.81% of liraglutide reports even though it isn't listed in that drug's product information (Popa Ilie et al., Pharmaceuticals, 2026, DOI (external link)). That tells you the reports exist across the class, but not how often hair loss actually happens.

Put together: hair loss is reported repeatedly and shows up more than on placebo in trials, the mechanism described below is well understood, and it hasn't been shown that the drugs cause it beyond the weight loss they produce.

What the research found

  • Tirzepatide, which produces the greatest average weight loss among these medications, was most often linked to telogen effluvium. That fits the idea that rapid weight loss itself is the main driver.
  • Semaglutide-related hair loss looked dose-dependent. Lower doses (under 2mg weekly, typical of diabetes treatment) were rarely implicated, while higher weight-management doses were more often associated with hair loss.
  • Women appeared disproportionately affected, in the review and in the Zepbound trial data.
  • Older GLP-1 medications (liraglutide, dulaglutide, exenatide) showed lower reported risk than semaglutide and tirzepatide, again consistent with the amount of weight lost mattering more than the drug class.

Why rapid weight loss causes shedding

Telogen effluvium is a well-documented response to physiological stress. Sudden weight loss, illness, surgery, childbirth, and severe calorie or protein restriction are all known triggers, with or without a GLP-1. Hair follicles shift early into their resting phase, and the extra shedding generally starts about 2–3 months after the trigger (Asghar et al., Cureus, 2020, DOI (external link)). So hair loss you notice today may reflect weight loss from a few months ago.

What tends to happen over time

Acute telogen effluvium is usually temporary, and the same review reports remission in around 95% of cases. Hair growth typically resumes once your weight stabilizes, though regrowth can take several months. Androgenetic alopecia is different: it's a permanent pattern, and the Gupta review also found it among the predominant subtypes in GLP-1 users, though it wasn't the type most often tied to the fastest weight loss.

What can help

Enough protein (see our guide on protein, fat, and carbohydrates) and overall nutritional adequacy support healthy hair growth, though they may not prevent stress-related shedding entirely. This matters more than it sounds. In a 2026 study of 387 adults on GLP-1 or dual GIP/GLP-1 medications, fewer than 10% met recommended protein intake (Korus et al., Journal of Translational Medicine, 2026, DOI (external link)), and severe protein deficiency and calorie restriction are themselves recognized triggers for telogen effluvium.

If hair loss is significant or distressing, raise it with your prescriber or a dermatologist. They can confirm which type of hair loss you have and talk through whether the pace of weight loss or your dose should change.

Study findings above are attributed to their authors and were located via PubMed.

This article is for general education and is not medical advice. Talk with your prescriber or care team about your own situation.

hair-lossalopeciaside-effects

Was this helpful?

Common questions

Questions people often ask about this topic.

  • Is hair loss really a side effect of GLP-1 medications?

    Yes. Hair loss is listed as an adverse reaction on the Zepbound label: in its weight-management trials, 4–5% of people on tirzepatide reported it compared with 1% on placebo, more often women than men. A 2026 systematic review of 24 studies found semaglutide and tirzepatide had the highest reported incidence, with telogen effluvium (temporary, stress-triggered shedding) and androgenetic alopecia the two most common types. What isn't established is whether the drug acts on hair follicles directly or whether the shedding is driven by rapid weight loss; the second explanation is the more plausible one.

  • If lots of people report it, why isn't the cause settled?

    Trial data show hair loss happens more often on the drug than on placebo, but they can't tell you whether the drug or the weight loss is responsible. Adverse-event databases don't settle it either: they capture reports, and public attention to a side effect drives up reporting whether or not the effect is common. When researchers applied standard statistical thresholds across four databases, GLP-1 hair-loss reports were the most numerous of any drug class but didn't cross the bar for a positive safety signal, and the authors called for intensive monitoring.

  • Will my hair grow back after GLP-1 hair loss?

    Telogen effluvium, the type most often tied to rapid weight loss, is usually temporary; one review reports remission in around 95% of acute cases. Hair growth typically resumes once your weight stabilizes, though regrowth can take several months. Androgenetic alopecia is a permanent pattern, and a 2026 review also found it among the predominant subtypes in GLP-1 users, so it's worth having a dermatologist confirm which type you have.

  • Why is my hair shedding months after I started losing weight?

    In telogen effluvium, hair follicles shift early into their resting phase, and the extra shedding generally starts about 2–3 months after the trigger. So hair loss you notice today may reflect weight loss from a few months ago.

  • Does the dose or drug matter for hair loss risk?

    A 2026 review found semaglutide-related hair loss looked dose-dependent: lower diabetes-range doses were rarely implicated, while higher weight-management doses were more often associated with it. Tirzepatide, which produces the greatest average weight loss, was most often linked to telogen effluvium, and older GLP-1 medications showed lower reported risk. That pattern fits the amount of weight lost mattering more than the drug class. Women appeared disproportionately affected.

  • What can I do about hair loss on a GLP-1?

    Eat enough protein and keep your overall nutrition adequate. This matters more than it sounds: in a 2026 study of 387 adults on GLP-1 medications, fewer than 10% met recommended protein intake, and severe protein deficiency and calorie restriction are recognized triggers for telogen effluvium. Good nutrition may not prevent stress-related shedding entirely. If hair loss is significant or distressing, raise it with your prescriber or a dermatologist to confirm the type of hair loss and discuss whether the pace of weight loss or your dose should change.

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

4Supporting

1Challenging

1Mixed findings

Revision history

Last updated · 5 revisions recorded.

Show what changed
  1. v5

    Evidence sources 3 → 6

  2. v4

    Common questions revised

  3. v3

    Summary rewritten; Body revised

  4. v2

    Body revised

  5. v1

    Existing article recorded at the start of version history

Improve this page

Community notes

Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.

Loading notes…

    New submissions are currently paused. Existing approved notes remain available.

    Related terms

    • Telogen effluvium — A temporary form of diffuse hair shedding that begins two to three months after a physical stressor — including rapid weight loss — pushes many hair follicles into their resting phase at once.
    • Pharmacovigilance — The science and practice of detecting, assessing, and preventing adverse effects of medications once they are in real-world use, after clinical trials end.
    • FAERS (FDA Adverse Event Reporting System, now AEMS) — The FDA's database of voluntary side-effect reports from patients, clinicians, and manufacturers, used to detect safety signals after a drug is on the market. In March 2026 it became part of the FDA Adverse Event Monitoring System (AEMS).
    • Lowest effective dose — The smallest dose of a medication that produces the intended benefit with tolerable side effects. It is a standard prescribing principle.

    Related guides